scholarly journals Evaluation of the analytical performance of the PC100 platelet counter

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Magdolna Nagy ◽  
Sepanta Fazaeli ◽  
René van Oerle ◽  
Hugo ten Cate ◽  
Marcel Schemmann ◽  
...  
Keyword(s):  
Platelet Count ◽  
Linear Relationship ◽  
Whole Blood ◽  
Point Of Care ◽  
Blood Platelet ◽  
Regression Equations ◽  
Median Difference ◽  
Platelet Counts ◽  
Reference Methods ◽  
Blood Platelet Count

Abstract Introduction Platelet count can be altered in various diseases and treatments and measuring it may provide better insight into the expected outcome. So far, quantification of platelet count is done within laboratory conditions by using established hematology analyzers, whereas a point-of-care device could be used for this purpose outside of the clinical laboratories. Aim Our aim was to assess the closeness of agreement between a newly developed point-of-care PC100 platelet counter and two reference methods (Sysmex® XP-300, Sysmex® XN-9000) in measuring platelet counts in whole blood and platelet-rich-plasma (PRP). Method Whole blood was obtained from 119 individuals, of which 74 were used to prepare PRP samples. Whole blood platelet count was measured by the two reference methods and the PC100 platelet counter. PRP was prepared from the whole blood and platelet count was adjusted to the range of 250–3600 × 103/μl and measured with the PC100 platelet counter and Sysmex® XP-300. Results A median difference of − 1.35% and − 2.98% occurred in whole blood platelet count between the PC100 platelet counter and the Sysmex® XP-300 and Sysmex® XN-9000, respectively. A strong linear correlation (r ≥ 0.98) was seen in both cases and regression equations indicated neither a constant nor a proportional bias between the methods. Direct comparison of the two reference methods revealed a median difference of − 1.15% and a strongly linear relationship (r = 0.99). Platelet count in PRP resulted in a median difference of 1.42% between the PC100 platelet counter and the reference method, Sysmex® XP-300. While the difference between two methods increased with concentration of platelets in PRP, a strong linear relationship remained throughout the whole measuring interval indicated by the high correlation coefficient (r = 0.99). Assessment of the predicted bias at predefined platelet counts showed that the bias in platelet counts falls within the acceptance criterion for both whole blood and PRP measurements. Conclusions Our results show that the PC100 platelet counter can be used interchangeably with the reference methods for determining platelet counts.

scholarly journals Methods: Blood Platelet Counts of the Golden Hamster, Cricetus auratus

Blood ◽  
1952 ◽  
Vol 7 (9) ◽  
pp. 948-949 ◽  
Author(s):  
KENNETH OTTIS ◽  
OSCAR E. TAUBER
Keyword(s):  
Platelet Count ◽  
Adult Male ◽  
Golden Hamster ◽  
Healthy Adult ◽  
Blood Platelet ◽  
Male And Female ◽  
Platelet Counts ◽  
Healthy Adult Male ◽  
Blood Platelet Count ◽  
Direct Counts

Abstract Healthy, adult male and female golden hamsters, 3 months of age, showed blood platelet count means of 688,000 ± 141,000 per cu. mm. and 742,000 ± 120,000 per cu. mm., respectively, when direct counts were made with siliconized pipets and with Rees and Ecker fluid as a diluent.

scholarly journals Perbedaan Hitung Jumlah Trombosit Menggunakan Darah Vena dan Darah Kapiler

2016 ◽  
Vol 3 (2) ◽  
pp. 81
Author(s):  
Hieronymus Rayi Prasetya ◽  
Maria Irena Dentri ◽  
Sistiyono Sistiyono
Keyword(s):  
Platelet Count ◽  
Blood Platelets ◽  
Venous Blood ◽  
Blood Platelet ◽  
Capillary Blood ◽  
Blood Capillaries ◽  
Blood Samples ◽  
Platelet Counts ◽  
Significant Difference ◽  
Blood Platelet Count

Background: Platelets play a role in hemostasis which is the body's mechanisms to prevent and stop the bleeding. Platelets participate in the effort to close the wound, so that the body does not experience a loss of blood and protected from foreign cells. Examination of the platelet count is very important in the diagnosis of diseases, one of which is the diagnosis of dengue hemorrhagic fever (DHF). Examination of blood counts, especially platelets in clinical laboratories causes blood samples in use are not always the venous blood but could use capillary blood. Capillary blood samples are used primarily in pediatric patients, because the venous blood sampling is difficult, patient loads, and also shorten the time when taking blood. The purpose of this study was to determine whether there is a difference in counting the number of platelets using samples of blood veins and capillaries. Methods: Quantitative research with observational approach using a cross sectional study design in the 30 samples of student D3 Health Analyst STIKes To Nation Yogyakarta. Statistical methods in use are independent T test. Results: The research subjects were 30 samples of student D3 Health Analyst STIKes To Nation Yogyakarta. The results of the examination of venous blood platelet count and blood capillaries have different average values ​​are 247 530 cells / ml of blood, for blood platelets veins and 184 270 cells / ml of blood for capillary blood platelets. Spearman correlation analysis Obtained results of the examination of venous blood platelet count and blood capillaries normal distribution (p> 0.05). 0.129 venous blood platelet counts, while the number of blood platelets kapilernya 0.089. Conclusion: There is a significant difference from the results of counting the number of blood platelets using veins and capillaries, where the use of capillary blood samples showed that lower platelet counts.

The Effect of Platelet Number and Haematocrit on Whole Blood Thromboxane Synthesis

1985 ◽  
Vol 53 (02) ◽  
pp. 225-227 ◽  
Author(s):  
A J Carter ◽  
S P Hanley
Keyword(s):  
Renal Failure ◽  
Platelet Count ◽  
Chronic Renal Failure ◽  
Whole Blood ◽  
Time Course ◽  
Normal Subjects ◽  
Blood Platelet ◽  
Glass Tubes ◽  
Blood Platelet Count ◽  
Edta Anticoagulated Blood

SummaryWhole blood, allowed to clot at 37° C in glass tubes, synthesized thromboxane A2 (TxA2) as determined by radioimmunoassay for thromboxane B2 (TxB2). The time course for TxB2 synthesis showed no further increase after 60 min and the concentration of TxB2 in serum obtained from 60 normal subjects positively correlated with the whole blood platelet count in EDTA anticoagulated blood from the same donor.Patients with chronic renal failure produced less serum TxB2 than age- and sex-matched controls; they also had lower haematocrits. After re-calculating TxB2 production as a function of platelet count and haematocrit all but one of the patients fell in the range of values obtained for controls. These results suggest that chronic renal failure may not be associated with a cyclooxygenase defect and that clotted whole blood TxB2 production should be expressed as a function of platelet count and haematocrit.

Platelet Aggregation in Rats in Relation to Hyperuricaemia Induced by Dietary Single-Cell Protein and to Protein Deficiency

1978 ◽  
Vol 39 (02) ◽  
pp. 346-359 ◽  
Author(s):  
P D Winocour ◽  
M R Turner ◽  
T G Taylor ◽  
K A Munday
Keyword(s):  
Uric Acid ◽  
Platelet Count ◽  
Platelet Aggregation ◽  
Time Lag ◽  
Blood Platelet ◽  
Single Cell Protein ◽  
Cell Protein ◽  
Low Protein ◽  
Blood Platelet Count ◽  
Rat Platelets

SummaryA major limitation to single-cell protein (SCP) as a human food is its high nucleic acid content, the purine moiety of which is metabolised to uric acid. Rats given a Fusarium mould as a source of SCP in diets containing oxonate, a uricase inhibitor, showed elevated plasma and kidney uric acid concentrations after 21 d, which were related to the level of dietary mould. ADP-induced and thrombin-induced platelet aggregation was greater in the hyperuricaemic rats than in controls and a progressive increase in aggregation with increasing levels of dietary mould was observed. Furthermore a time-lag, exceeding the life-span of rat platelets, was observed between the development of hyperuricaemia and the increase in aggregation. A similar time-lag was observed between the lowering of the hyperuricaemia and the reduction of platelet aggregation when oxonate was removed from the diet.If human platelets react to uric acid in the same manner as rat platelets this might explain the link that has been suggested between hyperuricaemia and ischaemic heart disease. In that event diets high in nucleic acids might be contra-indicated in people at risk from ischaemic heart disease.In rats given a low protein diet (50 g casein/kg) for 21 d ADP-induced and thrombin-induced platelet aggregation and whole blood platelet count were reduced compared with control animals receiving 200 g casein/kg diet but not in rats given 90 or 130 g casein/kg diet. A study of the time course on this effect indicated that the reduction both in aggregation tendency and in whole blood platelet count occurred after 4 d of feeding the low protein diet. These values were further reduced with time.

scholarly journals An introduction to point-of-care testing in extracorporeal circulation and LVADs

Hematology ◽  
2018 ◽  
Vol 2018 (1) ◽  
pp. 516-521 ◽  
Author(s):  
Rachel Sara Bercovitz
Keyword(s):  
Whole Blood ◽  
Point Of Care ◽  
Blood Platelet ◽  
Ventricular Assist Devices ◽  
Bleeding Complications ◽  
Future Research ◽  
Ventricular Assist ◽  
Assist Devices ◽  
Platelet Aggregometry ◽  
Coagulation Tests

Abstract There is a delicate balance between bleeding and clotting in patients on circuits such as ventricular assist devices or extracorporeal membrane oxygenation. Traditional coagulation tests, prothrombin time, activated partial thromboplastin time, and anti-factor Xa levels, are used to monitor patients on these devices. However, turnaround times and inability to assess global hemostasis, including platelets and fibrinogen have contributed to a recognition that faster, accurate, and more informative coagulation tests are needed. Activated clotting time is used to monitor heparin in patients on circuits and has the advantages of being a near-patient point-of-care test. However, its utility is limited to heparin monitoring. Viscoelastic tests (thromboelastometry and thromboelastography) are global, whole-blood coagulation tests, and whole-blood platelet aggregometry evaluates platelet function. Ideally, these tests can ensure that patients are within the therapeutic range of their antithrombotic medications, identify patients at risk for hemorrhagic or thrombotic complications, and guide management of acute bleeding complications. This ideal is currently hampered by a lack of studies that delineate clear ranges that are clinically relevant. Future research is needed to better understand the optimal use of point-of-care coagulation testing in patients on extracorporeal circuits and ventricular assist devices.

Gene Expression Profiling of Multiple Patients with Cyclic Thrombocytopenia Reveals Consistent Profile.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 219-219 ◽  
Author(s):  
Ruchira Sood ◽  
Erin Gourley ◽  
Stanley L. Schrier ◽  
Ronald Go ◽  
James L. Zehnder
Keyword(s):  
Gene Expression ◽  
Platelet Count ◽  
Gene Expression Profile ◽  
Expression Profile ◽  
Whole Blood ◽  
Gene Clusters ◽  
Underlying Disease ◽  
Multiple Time ◽  
Platelet Counts ◽  
History Of

Abstract Cyclic thrombocytopenia (CTP) is a rare disorder characterized by periodic changes in platelet count. While some previous reports suggest an association with several cytokines, the etiology of this disorder remains poorly characterized. Using DNA microarrays, we examined the gene expression profile in peripheral whole blood at multiple time points encompassing a cycle of platelet counts from two CTP patients. We hypothesized that the variation in gene expression program in whole blood would reflect on the transcriptional changes associated with or perhaps even underlying this disease. Genome-wide cDNA microarray analysis was performed using amplified RNA obtained from 11 and 8 whole blood samples from each patient. The first patient is a 41-year old male with a 2-year history of CTP while the second patient is a 54-year old male with a 3-year history of CTP. The period of both patients’ cycles is roughly 3 weeks. No associated underlying disease has been found in both patients. With a focus on 1500 genes that change 3 fold within each group of samples we observed clusters of gene expression in whole blood that correlate with changing platelet numbers in both patients. Significant variation in expression of a cluster of interferon responsive genes during the platelet count cycle was particularly striking in both samples. Interferon (IFN) therapy is known to suppress platelet counts, and this observation suggests that aberrant IFN levels and signalling could be in part responsible for CTP. At high platelet counts, platelet transcripts were detected in whole blood RNA as inferred by high expression of previously described platelet genes including TBXAS1, TUBB1, OAZ1, SEPT5, several mitochondrial genes, NRGN and F13A1. In addition, gene clusters including known genes as well as previously uncharacterized genes were found to correlate with the peak, increasing or decreasing trends of platelet counts. Briefly, GATA2 and NFE2 expression coincided with the platelet count peak, while Tyk2 and SOCS5 expression was consistent with a rising trend of platelet counts and GATA3 and JAK2 coincided with decreasing trend of platelet counts. These results show gene expression changes associated with CTP in all cell types in whole blood and pave the way for new investigation into regulation of platelet number in a rare and fascinating disease. Gene expression profile of whole blood of two CTP patients with platelet counts ranging from high to low and then increasing again from left to right of each panel Gene expression profile of whole blood of two CTP patients with platelet counts ranging from high to low and then increasing again from left to right of each panel

Recovery of Donor Peripheral Blood Platelet Count Following Platelet Apheresis.

Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 2892-2892
Author(s):  
Larry J. Dumont ◽  
L. Lassahn ◽  
Peter A. Tomasulo ◽  
Dennis Harpool ◽  
S. Pinkard ◽  
...  
Keyword(s):  
Platelet Count ◽  
Regression Model ◽  
Peripheral Blood ◽  
De Novo ◽  
Blood Platelet ◽  
Platelet Recovery ◽  
Platelet Release ◽  
Kinetics Of ◽  
Blood Platelet Count

Abstract BACKGROUND: Apheresis platelet collection from healthy normal blood donors can reduce the donor peripheral blood platelet concentration by 50% or more. The kinetics of peripheral blood platelet count (PLT) recovery in the apheresis donors over the first 24 hours has not been described. The objective of this study was to determine the recovery kinetics of the donor peripheral blood platelet count following apheresis platelet donation. METHODS: Healthy apheresis platelet donors were enrolled following informed consent. The apheresis platelet collection was performed using the Gambro Trima system (Gambro BCT, Lakewood, CO) following local SOP and manufacturer’s directions for use. The minimum predicted post-count was configured in the Trima to no less than 78K plt/μL. PLT was determined pre-procedure (Pre), immediately post procedure (Post), 4–11 h (FU1) and 11–41 h (FU2) post-donation using standard methods. The PLT recovery was evaluated as the increase in PLT following the donation (Delta). The effects of study site, time of sample, and the fraction of platelets collected (Fpc) at donation on Delta were evaluated using a random effects generalized linear regression model. A full regression model of Delta as a function of study site, follow-up period and Fpc with all main and interaction effects was used to test hypotheses. RESULTS: 548 subjects were entered into the study at 3 study sites; Pre-PLT 276±59 × 103 plt/μL, Post-PLT 205±47 × 103 plt/μL, Fpc 25±10%. No adverse events were reported by any subjects. Recovery of platelet count following apheresis platelet donation is variable between subjects; and the independent variables of study site, follow-period and Fpc accounted for 25% of the total variation in Delta. PLT increased 12.4±0.9 × 103 plt/μL by the time of follow-up sampling (p=0.01), although there was no difference between PLT at FU1 (214±49 × 103 plt/μL) and FU2 (212±47 × 103 plt/μL; p=0.15). None of the donors reached their pre-donation platelet count during the follow-up period. There was no difference in Delta between centers (p=0.23). Fpc had a significant affect on Delta (p<0.0001); with estimated Delta of 5.2±0.9 × 103 plt/μL at Fpc=15% and 16.0±.8 × 103 plt/μL at Fpc=30%. CONCLUSION: Platelet recovery following apheresis platelet donation was observed to be dependent on the fraction of platelets donated. Surprisingly, the recovery observed within the first 11 h was equivalent to that observed between 11–42 h, averaging 17.5% of the drop observed during apheresis. Recovery was not complete when observed for up to 41 h following donation in this study. Additional investigation of PLT recovery following apheresis donation is indicated to describe and differentiate the potential roles of de novo production, early pro-platelet release and platelet release from peripheral pools over the early post-donation period.

Sign in / Sign up

Export Citation Format

Share Document